Flexion Therapeutics Performance
The firm shows a Beta (market volatility) of 0.0, which means not very significant fluctuations relative to the market. the returns on MARKET and Flexion Therapeutics are completely uncorrelated.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Flexion Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy basic indicators, Flexion Therapeutics is not utilizing all of its potentials. The recent stock price disarray, may contribute to short-term losses for the investors. ...more
| Quick Ratio | 4.17 | |
| Fifty Two Week Low | 4.30 | |
| Target High Price | 27.00 | |
| Fifty Two Week High | 13.66 | |
| Target Low Price | 6.00 |
Flexion |
Flexion Therapeutics Relative Risk vs. Return Landscape
If you would invest (100.00) in Flexion Therapeutics on January 19, 2024 and sell it today you would earn a total of 100.00 from holding Flexion Therapeutics or generate -100.0% return on investment over 90 days. Flexion Therapeutics is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Flexion, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Flexion Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Flexion Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Flexion Therapeutics, and traders can use it to determine the average amount a Flexion Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| FLXN |
Based on monthly moving average Flexion Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Flexion Therapeutics by adding Flexion Therapeutics to a well-diversified portfolio.
Flexion Therapeutics Fundamentals Growth
Flexion Stock prices reflect investors' perceptions of the future prospects and financial health of Flexion Therapeutics, and Flexion Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Flexion Stock performance.
| Return On Asset | -18.99 | |||
| Profit Margin | (92.52) % | |||
| Operating Margin | (71.24) % | |||
| Current Valuation | 408.79 M | |||
| Shares Outstanding | 49.94 M | |||
| Price To Earning | (8.29) X | |||
| Price To Book | 35.88 X | |||
| Price To Sales | 4.43 X | |||
| Revenue | 102.74 M | |||
| EBITDA | (71.2 M) | |||
| Cash And Equivalents | 131.43 M | |||
| Cash Per Share | 2.61 X | |||
| Total Debt | 228.9 M | |||
| Book Value Per Share | (0.78) X | |||
| Cash Flow From Operations | (59.19 M) | |||
| Earnings Per Share | (2.20) X | |||
| Total Asset | 127.14 M | |||
| Retained Earnings | (686.19 M) | |||
| Current Asset | 112.1 M | |||
| Current Liabilities | 8.06 M | |||
Things to note about Flexion Therapeutics performance evaluation
Checking the ongoing alerts about Flexion Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Flexion Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Flexion Therapeutics is not yet fully synchronised with the market data | |
| Flexion Therapeutics has some characteristics of a very speculative penny stock | |
| Flexion Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 102.74 M. Net Loss for the year was (95.05 M) with profit before overhead, payroll, taxes, and interest of 66.53 M. | |
| Flexion Therapeutics currently holds about 131.43 M in cash with (59.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.61. | |
| Over 92.0% of the company shares are owned by institutional investors |
- Analyzing Flexion Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Flexion Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Flexion Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Flexion Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Flexion Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Flexion Therapeutics' stock. These opinions can provide insight into Flexion Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Other Consideration for investing in Flexion Stock
If you are still planning to invest in Flexion Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Flexion Therapeutics' history and understand the potential risks before investing.
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |